Metabolomic mapping of atypical antipsychotic effects in schizophrenia

• Published in: Molecular psychiatry Vol. 12; no. 10; pp. 934 - 945
• Main Authors: KADDURAH-DAOUK, R, MCEVOY, J, BAILLIE, R. A, LEE, D, YAO, J. K, DORAISWAMY, P. M, KRISHNAN, K. R. R
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.10.2007
• Subjects: Adult; Adult and adolescent clinical studies; Analysis of Variance; Antipsychotic Agents - pharmacology; Antipsychotic Agents - therapeutic use; Antipsychotic drugs; Antipsychotics; Aripiprazole; Biological and medical sciences; Care and treatment; Cohort Studies; Development and progression; Dosage and administration; Drugs; Fatty acids; Female; Humans; Hypertriglyceridemia; Lipid Metabolism - drug effects; Lipids; Lipids - blood; Male; Mapping; Medical sciences; Mental disorders; Metabolomics; Metabonomic analysis; Neuropharmacology; Olanzapine; Patients; Pharmacology. Drug treatments; Phenotypes; Phosphatidylethanolamine; Phospholipids; Principal Component Analysis; Psychiatric Status Rating Scales; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Psychoses; Psychotropic drugs; Risperidone; Schizophrenia; Schizophrenia - blood; Schizophrenia - drug therapy; Psychosis; Cartography; Chemotherapy; Atypical antipsychotic; Treatment; Neuroleptic; Psychotropic; metabolomics; Schizophrenia; antipsychotics; Lipidomics; metabolic profiling
• ISSN: 1359-4184; 1476-5578
• DOI: 10.1038/sj.mp.4002000

Schizophrenia is associated with impairments in neurotransmitter systems and changes in neuronal membrane phospholipids. Several atypical antipsychotic drugs induce weight gain and hypertriglyceridemia. To date, there has not been a comprehensive evaluation and mapping of global lipid changes in schizophrenia, and upon treatment with antipsychotics. Such mapping could provide novel insights about disease mechanisms and metabolic side effects of therapies used for its treatment. We used a specialized metabolomics platform 'lipidomics' that quantifies over 300 polar and nonpolar lipid metabolites (across seven lipid classes) to evaluate global lipid changes in schizophrenia and upon treatment with three commonly used atypical antipsychotics. Lipid profiles were derived for 50 patients with schizophrenia before and after treatment for 2-3 weeks with olanzapine (n=20), risperidone (n=14) or aripiprazole (n=16). Patients were recruited in two cohorts (study I, n=27 and study II, n=23) to permit an internal replication analyses. The change from baseline to post-treatment was then compared among the three drugs. Olanzapine and risperidone affected a much broader range of lipid classes than aripiprazole. Approximately 50 lipids tended to be increased with both risperidone and olanzapine and concentrations of triacylglycerols increased and free fatty acids decreased with both drugs but not with aripiprazole. Phosphatidylethanolamine concentrations that were suppressed in patients with schizophrenia were raised by all three drugs. Drug specific differences were also detected. A principal component analysis (PCA) identified baseline lipid alterations, which correlated with acute treatment response. A more definitive long-term randomized study of these drugs correlating global lipid changes with clinical outcomes could yield biomarkers that define drug-response phenotypes.